Gerresheimer's €1.5bn Divestment Arrives With a September Debt Deadline in the Wings
Published on 08/08/2026 at 17:53 | Redaktion boerse-global.de
The market's initial enthusiasm for Gerresheimer's blockbuster asset sale has cooled with remarkable speed. When the Düsseldorf-based packaging group announced on 29 July that it would offload two business units to an Apax Partners-led consortium, the shares jumped by a double-digit percentage. By the close of the following trading week, however, the stock had slipped back to €26.34, down 0.83 percent on the Friday alone and roughly 9.92 percent lower than a month earlier. The euphoria has given way to a harder-nosed assessment of what remains — and what still needs fixing.
A Deal Worth €1.5bn, and What It Means for the Balance Sheet
The transaction itself is substantial by any measure. Gerresheimer is selling Centor US Holding and its global Primary Packaging Plastics business to an Apax-managed fund complex, with the deal carrying an enterprise value of around €1.5 billion. The two divisions generated combined revenue of roughly €570 million in 2025 — more than a quarter of the group's total — and employ about 2,400 people across 16 plants in nine countries. The Centor sale is expected to close by the end of the current fiscal year 2026, while the plastics business will change hands in the first half of fiscal 2027. Morgan Stanley is acting as lead financial adviser, Commerzbank is providing fairness opinions, and Latham & Watkins is handling legal counsel.
Yet the divestment is not merely a portfolio-pruning exercise. It sits at the heart of a broader refinancing strategy that carries a hard deadline: a €870 million Schuldschein loan falls due by the end of September, and key financial covenants are currently suspended. Lazard has been brought in to oversee a full refinancing of the group's debt structure. The proceeds from the Apax deal are intended to lighten that load, but the timing gap between the sale announcement and the loan maturity leaves little room for complacency.
When a company's finances come under scrutiny, the operational risks hiding in plain sight often surface too. For UK employers, one of the most common gaps is a missing or outdated risk assessment — a legal requirement that can prove costly during any compliance review. A free toolkit with 41 ready-to-use templates and checklists helps you document hazards properly and stay on the right side of the law. Download the free Risk Assessment Toolkit
The Accounting Cloud That Won't Lift
The urgency behind the asset sale becomes clearer against the backdrop of the regulatory scrutiny that has dogged Gerresheimer for months. BaFin launched an examination of the group's condensed interim consolidated financial statements on 6 March, citing concrete indications of potential violations of accounting regulations. The probe was later expanded to cover leasing liabilities with a carrying amount of €65.5 million, potentially misstated useful lives of capitalised development costs totalling €29.4 million, and assets in the Advanced Technologies segment with a book value of €196.5 million that were impaired without the corresponding expense being recognised.
The fallout has been tangible. Gerresheimer was forced to leave the SDax in April after failing to deliver its 2024/25 annual report on time — a reputational blow that laid the trust crisis bare. The audited financial statements finally arrived at the end of June, accompanied by a lowered outlook. For 2026, the group now expects revenue in the lower half of the €2.3 billion to €2.4 billion range, with an adjusted EBITDA margin between 17 and 18 percent. Free cash flow is projected to land between minus €50 million and minus €100 million, partly due to reduced factoring volumes. No dividend will be paid for 2025, a consequence of the negative group result.
Analysts Split Down the Middle
The sell-side response to the divestment has been anything but uniform. On the day of the announcement, DZ Bank upgraded Gerresheimer to "Hold" with a fair value of €30. UBS struck a far more cautious tone, publishing a "Sell" rating on 27 July. ODDO BHF sits between the two, trimming its price target from €37 to €36 on the same day while maintaining an "Outperform" rating. Earlier in July, LBBW had raised its target from €23 to €28, keeping a Hold stance — a signal that at least some analysts saw the first signs of deleveraging as mildly encouraging, without dismissing the residual risks.
The divergence reflects a genuine uncertainty about the group's trajectory. For some, the sale demonstrates a credible path toward debt reduction and a sharper focus on the higher-margin pharmaceutical packaging core. For others, it raises questions about the operational substance of what remains — particularly given the group's anaemic 0.3 percent organic revenue growth in 2025, when it posted €2.3 billion in sales and €384 million in adjusted EBITDA.
A New Plant in China, a New Board in Düsseldorf
Operationally, Gerresheimer continues to push ahead in its core pharmaceutical franchise. On 23 July, the group commissioned a new plant in Zhenjiang Dagang, China, dedicated to pharmaceutical primary packaging made of glass. The facility, built over roughly four years on a 40,000-square-metre site, doubles the company's capacity for injectable drug packaging in China and creates around 300 jobs. It marks the fourth such plant under the joint venture with Shuangfeng Glass, a partnership now two decades old.
Shareholders will gather for the annual general meeting on 1 September, where the agenda includes boardroom changes. Dr Axel Herberg, Andrea Abt and Prof. Dr Annette G. Köhler are not standing for re-election to the supervisory board; Rainer Beaujean, Klaus Röhrig, Markus Sieger and Eva van Pelt are proposed as their successors. Dividend expectations are minimal, with the focus instead on whether management can credibly close the book on the accounting affair while executing the operational reset.
Regulatory probes and compliance failures can happen in any organisation — but the right documentation makes all the difference when inspectors come calling. Over 37,000 UK businesses use a free Health & Safety toolkit to stay aligned with key regulations like COSHH and PUWER. It includes ready-to-use risk assessments and checklists you can deploy immediately. Get the free Health & Safety Toolkit
The Market's Verdict So Far
The share price tells its own story. Over the past twelve months, Gerresheimer stock has lost 41.75 percent, leaving the company with a market capitalisation of €916.69 million — a figure that stands in stark contrast to the €1.5 billion the group is set to receive from the Apax deal alone. Institutional positioning remains fluid: Goldman Sachs has adjusted its voting rights stake several times recently, holding 19.67 percent as of 24 July, while short-seller D. E. Shaw increased its position to 1.52 percent by the end of July.
First-quarter 2026 figures, originally expected in late July or August, have yet to be published. With the Schuldschein deadline approaching and the accounting investigation ongoing, the coming weeks will test whether the Apax transaction marks the beginning of a genuine deleveraging story — or simply another chapter in a narrative dominated by lost trust.
